INTRODUCTION: Retinoids are natural and synthetic compounds part of the family of polyisoprenoid lipids. These compounds are involved in several important physiological processes in the human body because of their ability to bind to different nuclear receptors. Retinoids are used in the therapy of some precancerous lesions, the treatment of acute promyelocytic leukemia (APL), T-cell lymphoma, and the prevention of malignancies in high-risk cancer groups. In this work we discuss the possibilities for analysis of the newly synthesized hydrazone of the retinoid bexarotene.
AIM: The purpose of this study is to conduct FTIR spectral analysis of newly synthesized hydrazone of bexarotene.
MATERIALS AND METHODS: Infrared spectra 500-4000 cm-1 were taken on a Bruker FTIR spectrometer using ATR - a plug with Smart iTR adapter.
RESULTS: The infrared spectra of the newly synthesized compound were strikingly similar in the relative positions and intensities of the resulting peaks, confirming its close structural relationship with bexarotene. Despite the structural similarity, there were significant differences that point to the introduction of a substituent and the formation of a new hydrazone derivative.
CONCLUSION: In order to confirm the data obtained by FTIR spectroscopy, a further reversed-phase HPLC-UV analysis of the new hydrazone derivative should be performed.
Njar VC, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, et al. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem. 2006;14(13):4323-40. doi: 10.1016/j.bmc.2006.02.041.
Alizadeh F, Bolhassani A, Khavari A, Bathaie SZ, Naji T, Bidgoli SA. Retinoids and their biological effects against cancer. Int Immunopharmacol. 2014;18(1):43-9. doi: 10.1016/j.intimp.2013.10.027.
Sladek FM. What are nuclear receptor ligands? Mol Cell Endocrinol. 2011;334(1-2):3-13. doi: 10.1016/j.mce.2010.06.018.
Sever R, Glass CK. Signaling by nuclear receptors. Cold Spring Harb Perspect Biol. 2013;5(3):a016709. doi: 10.1101/cshperspect.a016709.
de Lera AR, Bourguet W, Altucci L, Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov. 2007;6(10):811-20. doi: 10.1038/nrd2398.
Corbett A, Williams G, Ballard C. Drug repositioning in Alzheimer's disease. Front Biosci (Schol Ed). 2015;7:184-8.
Furmick JK, Kaneko I, Walsh AN, Yang J, Bhogal JS, Gray GM, et al. Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene). ChemMedChem. 2012;7(9):1551-66. doi: 10.1002/cmdc.201200319.
Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev. 2010;62(13):1285-98. doi: 10.1016/j.addr.2010.07.003.
Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003;22(47):7305-15. doi: 10.1038/sj.onc.1206936
Guruswamy S, Lightfoot S, Gold MA, Hassan R, Berlin KD, Ivey RT, et al. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J Natl Cancer Inst. 2001;93(7):516-25. doi: 10.1093/jnci/93.7.516.
Magoulas GE, Bariamis SE, Athanassopoulos CM, Haskopoulos A, Dedes PG, Krokidis MG, et al. Syntheses, antiproliferative activity and theoretical characterization of acitretin-type retinoids with changes in the lipophilic part. Eur J Med Chem. 2011 Feb;46(2):721-37. doi: 10.1016/j.ejmech.2010.12.008.
Pilkington T, Brogden RN. Acitretin. A review of its pharmacology and therapeutic use. Drugs. 1992;43(4):597-627. doi: 10.2165/00003495-199243040-00010.
Rockley NL, Rockley MG, Halley BA, Nelson EC. Fourier transform infrared spectroscopy of retinoids. Methods Enzymol. 1986;123:92-101. doi: 10.1016/s0076-6879(86)23013-x.
Agova N, Georgieva S, Stoeva S, Stamova S, Mitkov J. HPLC method for analyzing new compounds – analogs of an antineoplastic drug. Bulg. Chem. Commun. 2020; 52(A):9-16. doi: 10.34049/bcc.52.A.271.
Email this article (Login required) 
